Similarly, a significant clinical benefit from platinum-based therapy has been demonstrated in patients with PC harboring a core HRD mutation (<9%), which includes germline or somatic BRCA1, BRCA2, and PALB2 mutations. Here, BRCA1 is linked to pachyonychia congenita.